文章基本信息

标题：Risk allocation of adult patients with non-M3 acute myeloid leukemia
本地全文：下载
作者：A. Venditti ; F. Buccisano ; L. Maurillo 等
期刊名称：Drugs and Cell Therapies in Hematology
印刷版ISSN：2281-4876
出版年度：2013
卷号：1
期号：1
页码：83-104
出版社：PAGEPress Publications
摘要：In acute myeloid leukemia (AML), cytogenetic/genetic assessment is universally recog- nized as a critical step since karyotypic and/or molecular abnormalities have been con- sistently shown to play a major prognostic role. At the same time, it is also very well known that cytogenetic/genetic signature may fail in predicting individual patient's outcome. In this view, minimal residual disease (MRD) detection promises to become a valuable bio- marker to assess the quality of response after chemotherapy and possibly outline post-re- missional programs based on the individual risk of relapse. As a matter of fact, the choice of post-remission therapy for adults with AML still largely relies on the one size fits all prin- ciple, therefore there is confidence that MRD determination will help refine risk-allocation leading to more appropriate, risk-adapted post-remissional interventions. In the present review, we will discuss the impact of cytogenetics and genetics on outcome of patients with AML and the role that a biomarker such as MRD might have if incorporated in our current risk-assessment algorithms. A comprehensive biological risk-assessment including cytogenetic/genetic profile and MRD determination would possibly allow tailored thera- peutic strategies to be adopted, avoiding situations of under or overtreatment
关键词：acute myeloid leukemia; cy- ; togenetics; genetics; minimal residual ; disease; flow cytometry; polymerase ; chain reaction